[1] [1] FENOLLAR F, PUCHAL X, RAOULT D. Whipple's disease[J]. N Engl J Med, 2007, 356(1): 55-66.

[2] [2] EL-ABASSI R, SOLIMAN M Y, WILLIAMS F, et al. Whipple's disease[J]. J Neurol Sci, 2017, 377: 197-206.

[3] [3] SCHOEDON G, GOLDENBERGER D, FORRER R, et al. Deactivation of macrophages with interleukin-4 is the key to the isolation ofTropheryma whippelii[J]. J Infect Dis, 1997, 176(3): 672-677.

[4] [4] AHMAD A I, WIKHOLM C, POTHOULAKIS I, et al. Whipple's disease review, prevalence, mortality, and characteristics in the United States: a cross-sectional national inpatient study[J]. Medicine (Baltimore), 2022, 101(49): e32231.

[5] [5] DOLMANS R A V, EDWIN BOEL C H, LACLE M M, et al. Clinical manifestations, treatment, and diagnosis ofTropheryma whippleiinfections[J]. Clin Microbiol Rev, 2017, 30(2): 529-555.

[7] [7] URBANSKI G, RIVEREAU P, ARTRU L, et al. Whipple disease revealed by lung involvement: a case report and literature review[J]. Chest, 2012, 141(6): 1595-1598.

[8] [8] LAGIER J C, FENOLLAR F, RAOULT D. Acute infections caused byTropheryma whipplei[J]. Future Microbiol, 2017, 12: 247-254.

[9] [9] ZHANG W M, XU L. Pulmonary parenchymal involvement caused byTropheryma whipplei[J]. Open Med (Wars), 2021, 16(1): 843-846.

[10] [10] LAGIER J C, LEPIDI H, RAOULT D, et al. SystemicTropheryma whipplei: clinical presentation of 142 patients with infections diagnosed or confirmed in a reference center[J]. Medicine (Baltimore), 2010, 89(5): 337-345.

[11] [11] LI W, ZHANG Q, XU Y L, et al. Severe pneumonia in adults caused byTropheryma whippleiandCandidasp. infection: a 2019 case series[J]. BMC Pulm Med, 2021, 21(1): 29.

[12] [12] HOFMANN P, DURISCH N, BUETIKOFER C, et al. Granulomatous lung disease and immune reconstitution inflammatory syndrome in Whipple's disease[J]. BMJ Case Rep, 2021, 14(6): e243633.

[13] [13] GUO Y F, LI L J, LI Z Z, et al.Tropheryma whippleidetection by nanopore sequencing in patients with interstitial lung disease[J]. Front Microbiol, 2021, 12: 760696.

[14] [14] LIN M M, WANG K Q, QIU L D, et al.Tropheryma whippleidetection by metagenomic next-generation sequencing in bronchoalveolar lavage fluid: a cross-sectional study[J]. Front Cell Infect Microbiol, 2022, 12: 961297.

[15] [15] FENOLLAR F, PONGE T, SCOLA B L, et al. First isolation ofTropheryma whippleifrom bronchoalveolar fluid and clinical implications[J]. J Infect, 2012, 65(3): 275-278.

[16] [16] SAMUELS T, HAMILTON P, SHAW P. Whipple disease of the mediastinum[J]. AJR Am J Roentgenol, 1990, 154(6): 1187-1188.

[17] [17] KUBASKA S M, SHEPARD J A, CHEW F S, et al. Whipple's disease involving the mediastinum[J]. AJR Am J Roentgenol, 1998, 171(2): 364.

[18] [18] TJANDRA D P, BRETT A, MURUGASU A. Use of bevacizumab in a patient with Whipple's disease: managing diagnostic uncertainty[J]. BMJ Case Rep, 2023, 16(10): e256460.

[19] [19] MACDERMOTT R P, GRAEME-COOK F M. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 37-1997. A 59-year-old man with anorexia, weight loss, and a mediastinal mass[J]. N Engl J Med, 1997, 337(22): 1612-1619.

[20] [20] BOUMAZA A, BEN AZZOUZ E, ARRINDELL J, et al. Whipple's disease andTropheryma whippleiinfections: from bench to bedside[J]. Lancet Infect Dis, 2022, 22(10): e280-e291.

[21] [21] GNTHER U, MOOS V, OFFENMLLER G, et al. Gastrointestinal diagnosis of classical Whipple disease: clinical, endoscopic, and histopathologic features in 191 patients[J]. Medicine (Baltimore), 2015, 94(15): e714.

[22] [22] FEURLE G E, JUNGA N S, MARTH T. Efficacy of ceftriaxone or meropenem as initial therapies in Whipple's disease[J]. Gastroenterology, 2010, 138(2): 478-486; quiz 11-12.

[23] [23] BAI J C, MAZURE R M, VAZQUEZ H, et al. Whipple's disease[J]. Clin Gastroenterol Hepatol, 2004, 2(10): 849-860.